title: Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation.
abstract: BACKGROUND
  Amiodarone use was associated with an increased need for pacemaker insertion in a retrospective study of patients with atrial fibrillation (AF) and prior myocardial infarction. The aims of this study were to determine prospectively whether amiodarone increases the need for pacemakers in a general population of patients with AF and whether this effect is modified by sex.
  
  
  METHODS
  The study included 1005 patients with new-onset AF who were enrolled in the Fibrillation Registry Assessing Costs, Therapies, Adverse events, and Lifestyle (FRACTAL). Multivariable Cox regression models, including time-dependent covariates accounting for medication exposure, were used to evaluate the risk of pacemaker insertion associated with amiodarone use.
  
  
  RESULTS
  Amiodarone use was associated with an increased risk of pacemaker insertion (hazard ratio [HR], 2.01; 95% confidence interval [CI], 1.08-3.76) after adjustment for age, sex, atrial flutter, coronary artery disease, heart failure, and hypertension. The effect of amiodarone use was modified by sex, with a significant risk in women but not in men (HR, 4.69; 95% CI, 1.99-11.05 vs HR, 1.05; 95% CI, 0.42-2.58 [P = .02]). This interaction remained significant after adjustment for weight, body mass index, weight-adjusted amiodarone dose, and use of other antiarrhythmic or rate control drugs.
  
  
  CONCLUSIONS
  The risk of bradyarrhythmia requiring pacemaker insertion associated with amiodarone use for AF is significantly greater in women than in men, independent of weight or body mass index.
authors: Division of Cardiology, McGill University Health Center, Montreal, Quebec, Canada.
authors: Vidal
authors: V
authors: Essebag
authors: Matthew R
authors: MR
authors: Reynolds
authors: Tom
authors: T
authors: Hadjis
authors: Robert
authors: R
authors: Lemery
authors: Brian
authors: B
authors: Olshansky
authors: Alfred E
authors: AE
authors: Buxton
authors: Mark E
authors: ME
authors: Josephson
authors: Peter
authors: P
authors: Zimetbaum
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000628:therapy*; D002304:Cardiac Pacing, Artificial / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012737:Sex Factors
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone
references: Lancet. 2000 Nov 25;356(9244):1789-94
references: 11117910
references: Circulation. 2005 Jun 14;111(23):3150-6; discussion 3156-7
references: 15956149
references: Scand Cardiovasc J. 2001 Oct;35(5):313-7
references: 11771822
references: J Gend Specif Med. 2002 Jan-Feb;5(1):25-33
references: 11859684
references: Clin Pharmacokinet. 2002;41(5):329-42
references: 12036391
references: N Engl J Med. 2002 Dec 5;347(23):1825-33
references: 12466506
references: N Engl J Med. 2002 Dec 5;347(23):1834-40
references: 12466507
references: J Am Coll Cardiol. 2003 Jan 15;41(2):249-54
references: 12535818
references: Fundam Clin Pharmacol. 2002 Oct;16(5):343-6
references: 12608357
references: Am J Cardiol. 2003 Mar 20;91(6A):39D-44D
references: 12670641
references: Arch Intern Med. 2003 Apr 14;163(7):777-85
references: 12695268
references: J Am Coll Cardiol. 2003 May 21;41(10):1690-6
references: 12767648
references: J Am Coll Cardiol. 2003 Jul 2;42(1):20-9
references: 12849654
references: J Cardiovasc Electrophysiol. 2003 Aug;14(8):791-9
references: 12890036
references: Br J Clin Pharmacol. 2003 Aug;56(2):198-204
references: 12895193
references: Annu Rev Pharmacol Toxicol. 2004;44:499-523
references: 14744256
references: Clin Pharmacol Ther. 2004 Apr;75(4):342-51
references: 15060512
references: Chest. 2004 Aug;126(2):476-86
references: 15302734
references: Int J Clin Pharmacol Ther. 2004 Aug;42(8):463-72
references: 15366327
references: Am J Med. 1987 Jun;82(6):1102-8
references: 3605129
references: Can J Cardiol. 1991 Apr;7(3):117-24
references: 2044013
references: In Vivo. 1990 Mar-Apr;4(2):97-100
references: 2129806
references: JAMA. 1993 Dec 1;270(21):2590-7
references: 8230644
references: Circulation. 1999 Nov 9;100(19):2025-34
references: 10556230
references: J Clin Pharm Ther. 1999 Oct;24(5):339-46
references: 10583696
references: Clin Pharmacol Ther. 1999 Dec;66(6):594-601
references: 10613615
references: N Engl J Med. 2000 Mar 30;342(13):913-20
references: 10738049
references: Clin Pharmacol Ther. 2000 Sep;68(3):286-92
references: 11014410
references: Am J Med. 1996 May;100(5):537-43
references: 8644766
references: Ann Intern Med. 1997 Aug 15;127(4):281-4
references: 9265427
references: J Am Coll Cardiol. 1997 Sep;30(3):791-8
references: 9283542
references: Cardiovasc Res. 1997 Jul;35(1):13-29
references: 9302343
references: J Clin Pharmacol. 1998 Nov;38(11):1003-9
references: 9824780
references: Am Heart J. 2006 Dec;152(6):1097-103
references: 17161061
references: J Cardiovasc Electrophysiol. 2007 Jun;18(6):628-33
references: 17451468
references: Annu Rev Public Health. 1999;20:145-57
references: 10352854
references: Ann Intern Med. 2004 Nov 2;141(9):720-6
references: 15520430
references: Pacing Clin Electrophysiol. 2004 Nov;27(11):1519-25
references: 15546307
references: BMC Med Res Methodol. 2005 Jan 25;5(1):5
references: 15670334
references: Isr Med Assoc J. 2005 Mar;7(3):163-5
references: 15792261
references: N Engl J Med. 2005 May 5;352(18):1861-72
references: 15872201
references: Int J Toxicol. 2001 May-Jun;20(3):149-52
references: 11488556